Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers

Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Early identification of high-risk patients before surgery is important for improving treatment decisions and patient management.

This study aims to develop a prediction model based on routinely available preoperative blood test results and clinical characteristics to estimate the risk of postoperative complications and long-term survival in patients with gastric cancer. The model will be developed and validated using data from multiple medical centers.

By using easily accessible clinical information, this study seeks to provide a practical tool to help clinicians better assess patient risk before surgery, support personalized treatment planning, and improve overall patient outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastric Cancers Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients aged ≥18 years;
patients diagnosed with gastric cancer by pathological biopsy before surgery;
patients without chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
willing to participate in this study and sign the informed consent;
complete clinical data.

Exclusion criteria

patients with other primary malignant tumours other than gastric cancer;
patients with systemic diseases such as severe cardiopulmonary insufficiency that affect the choice of treatment plan;
patients who are not suitable for enrolment as assessed by the investigator;
incomplete clinical data.

Treatment and study plan

gastric cancer

Diagnostic Test

be diagnosed as gastric cancer

Primary outcomes

the incidence of gastric cancer

Time frame: From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.

the diagnosis time of gastric cancer

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Chongqing Medical University

Other

Registry information

Official study title

Clinical Study on the Effect of Preoperative Serum Biomarkers on the Prognosis of Gastric Cancer

Important dates

Study start: 2010
Primary completion: 2024
Study completion: 2024
First posted: Nov 13, 2024
Registry last updated: Mar 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed